Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science

Compston, Juliet; Reid, David M.; Boisdron, J.; Brandi, Maria Luisa; Burlet, Nansa; Cahall, David; Delmas, PD; Dere, Willard H.; Devogelaer, J.-P.; Fitzpatrick, Lorraine A.; Flamion, Bruno; Goel, Niti; Korte, Sven; Laslop, Andrea; Mitlak, Bruce; Ormarsdóttir, Sif; Ringe, J. D.; Rizzoli, René; Tsouderos, Y; Staa, TP Van; Reginster, Jean-Yves

doi:10.1007/s00198-008-0735-7

Cited by 8 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[17][18][19][20][21] These changes are similar in some respects to those seen in postmenopausal osteoporosis, but differ in others. 22 In postmenopausal osteoporosis, the increase in resorption at the tissue level is maintained and accompanied by increased tissue-level bone formation. Both GIO and postmenopausal osteoporosis are associated with a reduction in bone formation at the cellular level, this effect being quantitatively greater in GIO.…”

Section: Reviewsmentioning

confidence: 99%

Management of glucocorticoid-induced osteoporosis

2010

View full text Add to dashboard Cite

Glucocorticoid-induced osteoporosis is a common condition that results in significant morbidity and mortality. The skeletal effects of glucocorticoids include both direct and indirect actions on bone that result in an early, transient increase in bone resorption accompanied by a decrease in bone formation, which is maintained for the duration of glucocorticoid therapy. Rapid bone loss and increased fracture risk occur soon after the initiation of glucocorticoid therapy and are dose dependent. The increase in fracture risk is partly independent of bone mineral density, probably as a result of changes in bone material properties and an increased risk of falling. Bisphosphonates are the front-line choice for prevention of fracture in glucocorticoid-treated patients, with teriparatide as the second-line option; calcium and vitamin D supplements should be co-prescribed in the majority of individuals. Future guidelines for the management of glucocorticoid-induced osteoporosis should recognize the limitations of FRAX in assessing fracture risk in glucocorticoid-treated patients, and should include recently approved interventions, such as zoledronate and teriparatide.

show abstract

Section: Reviewsmentioning

confidence: 99%

Management of glucocorticoid-induced osteoporosis

2010

View full text Add to dashboard Cite

show abstract

“…Perhaps, this increase in BMD is to be expected as increased X-ray absorption of strontium leads to an amplification of bone mineral density measurement by dual-photon X-ray absorptiometry when bone mineral density is expressed as a calcium hydroxyapatite equivalent. However, more importantly, the fact that the increases in BMD achieved in GIOP with strontium ranelate are of the same magnitude as shown for postmenopausal osteoporosis [26] suggests that a comparable fracture-reducing effect may be expected. The data are encouraging and suggest that it would be worth performing a prospective randomized clinical trial with strontium ranelate in GIOP.…”

Section: Glucocorticoid Usementioning

confidence: 78%

Strontium ranelate: an effective solution for diverse fracture risks

Ringe

2010

Osteoporos Int

View full text Add to dashboard Cite

Osteoporosis is listed by the WHO among the ten most frequent and socio-economically important, chronic diseases of mankind. The term osteoporosis however comprises a number of different pathophysiological conditions and clinical situations of weakened bones with increased risk of fragility fractures. A modern anti-osteoporotic drug should provide qualified study results proving therapeutic efficacy over this broad range of daily clinical appearances of osteoporosis. The decision for treatment in the individual patients depends no longer only on bone mineral density. Today, the major criterion for decision making is the prospective 10-year risk for fractures. Since this risk is calculated on the basis of age, sex, bone mineral density, prevalent fractures, and a number of other contributing risk factors (Kanis et al., Osteoporos Int 12:989-995, 2001; Kanis et al., Osteoporos Int 19:385-397, 2008), it seems to be of interest to have a look whether the fracture-reducing potency of a drug is influenced by these risk factors. The purpose of this review is to analyze whether the fracture-reducing efficacy of strontium ranelate in patients with osteoporosis can be achieved independently of sex, etiology of osteoporosis, and the major diagnostically relevant risk factors.

show abstract

“…This meeting was organized by the Group for the Respect of Ethics and Excellence in Science (GREES). This nonprofit organization has expertise in literature research and in expert consensus meetings [36][37][38][39][40][41][42][43][44].…”

Section: Methodsmentioning

confidence: 99%